Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions

Journal of Neurology

Volumn 262, Issue 4, 2015, Pages 1081-1095

  Varley, James ^a   Vincent, Angela ^a   Irani, Sarosh R ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Autoantibodies; Autoimmune encephalitis; CASPR2; Cell surface; LGI1; NMDA receptor

Indexed keywords

AUTOANTIBODY;

ANIMAL; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; HUMAN; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; HUMANS;

EID: 84939983766     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7600-8     Document Type: Article

References (127)

1. Leypoldt F, Wandinger KP (2014) Paraneoplastic neurological syndromes. Clin Exp Immunol 175(3):336–348
2. McKeon A, Pittock SJ (2011) Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 122(4):381–400
3. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE et al (2007) Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61(1):25–36
4. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P et al (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133(9):2734–2748
5. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C et al (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12(2):157–165
6. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA (2012) The frequency of autoimmune N-methyl-d-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 54(7):899–904
7. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S et al (2010) N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 133(Pt 6):1655–1667
8. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098
9. Florance NR, Davis RL, Lam C, Szperka C, Zhou L et al (2009) Anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 66(1):11–18
10. Zandi MS, Irani SR, Lang B, Waters P, Jones PB et al (2011) Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 258(4):686–688
11. Niehusmann P, Dalmau J, Rudlowski C, Vincent A, Elger CE et al (2009) Diagnostic value of N-methyl-d-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 66(4):458–464
12. Outteryck O, Baille G, Hodel J, Giroux M, Lacour A et al (2013) Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurol 13:211
13. Cobo-Calvo A, Izquierdo Gracia C, Quinones SM, Torro CM, Saiz A et al (2014) Optic neuritis in the setting of NMDA receptor encephalitis. J Neuro-ophthalmol 34(3):316–319
14. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33(5):634–643
15. Hanly JG (2014) Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 10(6):338–347
16. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ et al (2009) AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 65(4):424–434
17. Sprengel R (2006) Role of AMPA receptors in synaptic plasticity. Cell Tissue Res 326(2):447–455
18. Graus F, Boronat A, Xifro X, Boix M, Svigelj V et al (2010) The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 74(10):857–859
19. Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L et al (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131(Pt 10):2553–2563
20. Mata S, Muscas GC, Naldi I, Rosati E, Paladini S et al (2008) Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol 199(1–2):155–159
21. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67(4):470–478
22. Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M et al (2007) Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 61(6):544–551
23. Christgau S, Aanstoot HJ, Schierbeck H, Begley K, Tullin S et al (1992) Membrane anchoring of the autoantigen GAD65 to microvesicles in pancreatic beta-cells by palmitoylation in the NH2-terminal domain. J Cell Biol 118(2):309–320
24. Chavez-Valdez R, Martin LJ, Flock DL, Northington FJ (2012) Necrostatin-1 attenuates mitochondrial dysfunction in neurons and astrocytes following neonatal hypoxia-ischemia. Neuroscience 219:192–203
25. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R et al (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9(1):67–76
26. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F (2011) GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 76(9):795–800
27. Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E et al (2014) Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 137(Pt 8):2178–2192
28. Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T et al (2014) Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 13(3):276–286
29. Chang T, Alexopoulos H, McMenamin M, Carvajal-Gonzalez A, Alexander SK et al (2013) Neuronal surface and glutamic acid decarboxylase autoantibodies in nonparaneoplastic stiff person syndrome. JAMA Neurol 70(9):1140–1149
30. Meinck HM, Thompson PD (2002) Stiff man syndrome and related conditions. Mov Disord 17(5):853–866
31. Irani SR, Gelfand JM, Al-Diwani A, Vincent A (2014) Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol 76(2):168–184
32. Hutchinson M, Waters P, McHugh J, Gorman G, O’Riordan S et al (2008) Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 71(16):1291–1292
33. Damasio J, Leite MI, Coutinho E, Waters P, Woodhall M et al (2013) Progressive encephalomyelitis with rigidity and myoclonus: the first pediatric case with glycine receptor antibodies. JAMA Neurol 70(4):498–501
34. Turner MR, Irani SR, Leite MI, Nithi K, Vincent A et al (2011) Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies. Neurology 77(5):439–443
35. Mundiyanapurath S, Jarius S, Probst C, Stocker W, Wildemann B et al (2013) GABA-B-receptor antibodies in paraneoplastic brainstem encephalitis. J Neuroimmunol 259(1–2):88–91
36. Kim TJ, Lee ST, Shin JW, Moon J, Lim JA et al (2014) Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. J Neuroimmunol 270(1–2):45–50
37. Ohkawa T, Satake S, Yokoi N, Miyazaki Y, Ohshita T et al (2014) Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. J Neurosci 34(24):8151–8163
38. Hart IK, Waters C, Vincent A, Newland C, Beeson D et al (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41(2):238–246
39. Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P et al (2012) Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol 72(2):241–255
40. Liguori R, Vincent A, Clover L, Avoni P, Plazzi G et al (2001) Morvan’s syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124(Pt 12):2417–2426
41. Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M et al (2004) Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62(7):1177–1182
42. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK et al (2004) Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127(Pt 3):701–712
43. Barajas RF, Collins DE, Cha S, Geschwind MD (2010) Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia 51(3):473–477
44. Irani SR, Michell AW, Lang B, Pettingill P, Waters P et al (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69(5):892–900
45. Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA et al (2013) Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136(Pt 10):3151–3162
46. McKnight K, Jiang Y, Hart Y, Cavey A, Wroe S et al (2005) Serum antibodies in epilepsy and seizure-associated disorders. Neurology 65(11):1730–1736
47. Klein CJ, Lennon VA, Aston PA, McKeon A, Pittock SJ (2012) Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology 79(11):1136–1144
48. Becker EB, Zuliani L, Pettingill R, Lang B, Waters P et al (2012) Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry 83(4):437–440
49. Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS (2006) Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 129(Pt 6):1570–1584
50. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L et al (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9(8):776–785
51. Fukata Y, Lovero KL, Iwanaga T, Watanabe A, Yokoi N et al (2010) Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Nat Acad Sci USA 107(8):3799–3804
52. Malter MP, Frisch C, Schoene-Bake JC, Helmstaedter C, Wandinger KP et al (2014) Outcome of limbic encephalitis with VGKC-complex antibodies: relation to antigenic specificity. J Neurol 261(9):1695–1705
53. Klein CJ, Lennon VA, Aston PA, McKeon A, O’Toole O et al (2013) Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 70(2):229–234
54. Buckley C, Oger J, Clover L, Tuzun E, Carpenter K et al (2001) Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 50(1):73–78
55. Szots M, Marton A, Kover F, Kiss T, Berki T et al (2014) Natural course of LGI1 encephalitis: 3–5 years of follow-up without immunotherapy. J Neurol Sciences 343(1–2):198–202
56. Shin YW, Lee ST, Shin JW, Moon J, Lim JA et al (2013) VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 265(1–2):75–81
57. Lilleker JB, Jones MS, Mohanraj R (2013) VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure 22(9):776–779
58. Plantone D, Renna R, Grossi D, Plantone F, Iorio R (2013) Teaching NeuroImages: basal ganglia involvement in facio-brachial dystonic seizures associated with LGI1 antibodies. Neurology 80(17):e183–e184
59. Quek AM, Britton JW, McKeon A, So E, Lennon VA et al (2012) Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 69(5):582–593
60. Irani SR, Buckley C, Vincent A, Cockerell OC, Rudge P et al (2008) Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology 71(20):1647–1648
61. Yoo JY, Hirsch LJ (2014) Limbic encephalitis associated with anti-voltage-gated potassium channel complex antibodies mimicking Creutzfeldt-Jakob disease. JAMA Neurol 71(1):79–82
62. Rocamora R, Becerra JL, Fossas P, Gomez M, Vivanco-Hidalgo RM et al (2014) Pilomotor seizures: an autonomic semiology of limbic encephalitis? Seizure 23(8):670–673
63. Naasan G, Irani SR, Bettcher BM, Geschwind MD, Gelfand JM (2014) Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol 71(10):1300–1304
64. Gu C, Gu Y (2011) Clustering and activity tuning of Kv1 channels in myelinated hippocampal axons. J Biol Chem 286(29):25835–25847
65. Sharma S, Sharma P (2013) Morvan syndrome: after scrotal sac drainage and chemical instillation in hydrocele. Neurol India 61(3):300–302
66. Olberg H, Haugen M, Storstein A, Vedeler CA (2013) Neurological manifestations related to level of voltage-gated potassium channel antibodies. J Neurol Neurosurg Psychiatry 84(8):941–943
67. Paterson RW, Zandi MS, Armstrong R, Vincent A, Schott JM (2014) Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry 85(6):625–630
68. Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M et al (2013) Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 73(1):120–128
69. Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL et al (2014) DPPX potassium channel antibody: Frequency, clinical accompaniments, and outcomes in 20 patients. Neurology 83(20):1797–1803
70. Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J et al (2014) A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 13(6):575–586
71. Angus-Leppan H, Rudge P, Mead S, Collinge J, Vincent A (2013) Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol 70(7):919–922
72. Rossi M, Mead S, Collinge J, Rudge P, Vincent A (2014) Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (in press)
73. Lalic T, Pettingill P, Vincent A, Capogna M (2011) Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission. Epilepsia 52(1):121–131
74. Ohkawa T, Fukata Y, Yamasaki M, Miyazaki T, Yokoi N et al (2013) Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 33(46):18161–18174
75. Bien CG, Vincent A, Barnett MH, Becker AJ, Blumcke I et al (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135(Pt 5):1622–1638
76. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M et al (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130(Pt 5):1224–1234
77. Forrest D, Yuzaki M, Soares HD, Ng L, Luk DC et al (1994) Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 13(2):325–338
78. Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G et al (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13(1):76–83
79. McNamara RK, Skelton RW (1996) Baclofen, a selective GABAB receptor agonist, dose-dependently impairs spatial learning in rats. Pharmacol Biochem Behav 53(2):303–308
80. Schuler V, Luscher C, Blanchet C, Klix N, Sansig G et al (2001) Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron 31(1):47–58
81. Xi B, Chen J, Yang L, Wang W, Fu M et al (2011) GABBR1 gene polymorphism(G1465A)isassociated with temporal lobe epilepsy. Epilepsy Res 96(1–2):58–63
82. Zai G, King N, Wong GW, Barr CL, Kennedy JL (2005) Possible association between the gamma-aminobutyric acid type B receptor 1 (GABBR1) gene and schizophrenia. Eur Neuropsychopharmacol 15(3):347–352
83. Zai G, Arnold P, Burroughs E, Barr CL, Richter MA et al (2005) Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive-compulsive disorder. Am J Med Genet Part B Neuropsychiatric Genet 134B(1):25–29
84. Yu YE, Wen L, Silva J, Li Z, Head K et al (2010) Lgi1 null mutant mice exhibit myoclonic seizures and CA1 neuronal hyperexcitability. Hum Mol Genet 19(9):1702–1711
85. Zhou YD, Lee S, Jin Z, Wright M, Smith SE et al (2009) Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat Med 15(10):1208–1214
86. Nobile C, Michelucci R, Andreazza S, Pasini E, Tosatto SC et al (2009) LGI1 mutations in autosomal dominant and sporadic lateral temporal epilepsy. Hum Mutat 30(4):530–536
87. Gu W, Brodtkorb E, Steinlein OK (2002) LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol 52(3):364–367
88. Kinali M, Jungbluth H, Eunson LH, Sewry CA, Manzur AY et al (2004) Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia. Neuromuscul Disord 14(10):689–693
89. Zuberi SM, Eunson LH, Spauschus A, De Silva R, Tolmie J et al (1999) A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain 122(Pt 5):817–825
90. Poliak S, Salomon D, Elhanany H, Sabanay H, Kiernan B et al (2003) Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. J Cell Biol 162(6):1149–1160
91. Penagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A et al (2011) Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell 147(1):235–246
92. Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV et al (2008) Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 82(1):150–159
93. Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE et al (2006) Recessive symptomatic focal epilepsy and mutant contactin-associated protein-like 2. N Engl J Med 354(13):1370–1377
94. Friedman JI, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA et al (2008) CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry 13(3):261–266
95. Leypoldt F, Armangue T, Dalmau J (2014) Autoimmune encephalopathies. Ann N Y Acad Sci (in press)
96. Zandi MS, Paterson RW, Ellul MA, Jacobson L, Al-Diwani A et al. (2014) Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes. J Neurol Neurosurg Psychiatry (in press)
97. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L et al (2010) Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 30(17):5866–5875
98. Dahm L, Ott C, Steiner J, Stepniak B, Teegen B et al (2014) Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol 76(1):82–94
99. Pruss H, Holtje M, Maier N, Gomez A, Buchert R et al (2012) IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology 78(22):1743–1753
100. Choe CU, Karamatskos E, Schattling B, Leypoldt F, Liuzzi G et al (2013) A clinical and neurobiological case of IgM NMDA receptor antibody associated encephalitis mimicking bipolar disorder. Psychiatry Res 208(2):194–196
101. Armangue T, Titulaer MJ, Malaga I, Bataller L, Gabilondo I et al (2013) Pediatric anti-N-methyl-d-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 162(4):850–856
102. Hacohen Y, Deiva K, Pettingill P, Waters P, Siddiqui A et al (2014) N-methyl-d-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord 29(1):90–96
103. Mackay G, Ahmad K, Stone J, Sudlow C, Summers D et al (2012) NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol 259(9):1979–1981
104. Lachance DH, Lennon VA, Pittock SJ, Tracy JA, Krecke KN et al (2010) An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol 9(1):55–66
105. Meeusen JW, Klein CJ, Pirko I, Haselkorn KE, Kryzer TJ et al (2012) Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol. Ann Neurol 71(3):417–426
106. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474–481
107. Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A et al (2011) Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 69(2):303–311
108. Hoftberger R, Titulaer MJ, Sabater L, Dome B, Rozsas A et al (2013) Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 81(17):1500–1506
109. Cree BA, Lamb S, Morgan K, Chen A, Waubant E et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7):1270–1272
110. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y et al (2007) Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Multiple Scler 13(1):128–132
111. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443–1448
112. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114
113. Brodtkorb E, Gu W, Nakken KO, Fischer C, Steinlein OK (2002) Familial temporal lobe epilepsy with aphasic seizures and linkage to chromosome 10q22-q24. Epilepsia 43(3):228–235
114. Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y et al (2011) Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet 88(3):306–316
115. Manahan-Vaughan D, von Haebler D, Winter C, Juckel G, Heinemann U (2008) A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 18(2):125–134
116. Curran HV, Morgan C (2000) Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 95(4):575–590
117. Prosser HM, Gill CH, Hirst WD, Grau E, Robbins M et al (2001) Epileptogenesis and enhanced prepulse inhibition in GABA(B1)-deficient mice. Mol Cell Neurosci 17(6):1059–1070
118. Wernicke C, Samochowiec J, Schmidt LG, Winterer G, Smolka M et al (2003) Polymorphisms in the N-methyl-d-aspartate receptor 1 and 2B subunits are associated with alcoholism-related traits. Biol Psychiatry 54(9):922–928
119. Zhao X, Li H, Shi Y, Tang R, Chen W et al (2006) Significant association between the genetic variations in the 5′ end of the N-methyl-d-aspartate receptor subunit gene GRIN1 and schizophrenia. Biol Psychiatry 59(8):747–753
120. Chanasong R, Thanoi S, Watiktinkorn P, Reynolds GP, Nudmamud-Thanoi S (2013) Genetic variation of GRIN1 confers vulnerability to methamphetamine-dependent psychosis in a Thai population. Neurosci Lett 551:58–61
121. Epi KC, Phenome Epilepsy, Genome P, Allen AS, Berkovic SF, Cossette P et al (2013) De novo mutations in epileptic encephalopathies. Nature 501(7466):217–221
122. Bennett DR, Madsen JA, Jordan WS, Wiser WC (1973) Ketamine anesthesia in brain-damaged epileptics. Electroencephalographic and clinical observations. Neurology 23(5):449–460
123. Badran S, Schmutz M, Olpe HR (1997) Comparative in vivo and in vitro studies with the potent GABAB receptor antagonist, CGP 56999A. Eur J Pharmacol 333(2–3):135–142
124. Taittonen MT, Kirvela OA, Aantaa R, Kanto JH (1998) The effect of clonidine or midazolam premedication on perioperative responses during ketamine anesthesia. Anesth Analg 87(1):161–167
125. McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA (1981) Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 10(5):237–242
126. Marco LA, Joshi RS (1992) A ketamine-induced rat model of tardive dyskinesia. Prog Neurobiol 38(6):571–600
127. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167(1):127–135